Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorcaserin and Fitbit for Cannabis Use Disorder
NCT02932215Phase 1Completed
- Sponsor
- New York State Psychiatric Institute
- Start
- Oct 2016
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lorcaserin in cannabis use disorder (CUD), sponsored by New York State Psychiatric Institute. Primary endpoints: Cannabis use reduction, Adherence to wearing the device and 3 more. Started Oct 2016; status: completed.
02
Drugs
lorcaserin
03
Conditions
cannabis use disorder (CUD)
Beyond the preview
Go deeper on NCT02932215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02932215.